Deutsche Bank AG Acquires New Stake in Aurinia Pharmaceuticals Inc $AUPH

Deutsche Bank AG acquired a new stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 210,005 shares of the biotechnology company’s stock, valued at approximately $3,564,000.

A number of other large investors have also bought and sold shares of AUPH. BOK Financial Private Wealth Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $32,000. Global Retirement Partners LLC bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $41,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth about $48,000. Frazier Financial Advisors LLC raised its stake in Aurinia Pharmaceuticals by 411.9% in the 1st quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 2,793 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at about $82,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on AUPH. Zacks Research lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada boosted their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Finally, Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Insider Transactions at Aurinia Pharmaceuticals

In other news, CEO Kevin Tang purchased 206,005 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was purchased at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the acquisition, the chief executive officer directly owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 814,606 shares of company stock valued at $12,455,129. Corporate insiders own 10.40% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 1.3%

Shares of AUPH opened at $16.54 on Thursday. Aurinia Pharmaceuticals Inc has a twelve month low of $10.34 and a twelve month high of $19.25. The stock has a market cap of $2.20 billion, a PE ratio of 7.22 and a beta of 1.42. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The business’s 50-day moving average price is $15.98 and its 200-day moving average price is $15.47.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million during the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.